News

Investors Bet on Biotech as Public Cancer Research Hits a Wall
Baystreet.caNews Commentary – As cancer rates continue to climb worldwide, the race to develop better, faster, and more ...
Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices
Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have ...
finanzen.at4d
EQS-News: GeoVax Comments on FDA Approval of Keytruda(R) in Head and Neck Cancer, Underscoring Potential for Gedeptin(R) Combination Therapy
GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today commented on the U.S. Food and ...
Fierce Biotech5d
Exelixis' blockbuster hopeful beats Bayer drug in pivotal cancer trial, sending stock higher
A combination featuring Exelixis’ experimental drug zanzalintinib has beaten Bayer’s gastrointestinal cancer med Stivarga in ...